国际眼科杂志
國際眼科雜誌
국제안과잡지
INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
2014年
8期
1444-1446
,共3页
曲伏前列素%眼内压%青光眼%人工晶状体
麯伏前列素%眼內壓%青光眼%人工晶狀體
곡복전렬소%안내압%청광안%인공정상체
travoprost%intraocular pressure%glaucoma%intraocular lens
目的：观察曲伏前列素滴眼液对已行白内障超声乳化人工晶状体植入术的原发性开角型青光眼患者的降眼压效果及安全性。<br> 方法：采用随机、单盲、平行对照试验,选取白内障超声乳化人工晶状体植入术后的原发性开角型青光眼患者,治疗组入选43例43眼滴用曲伏前列素每日1次,对照组入选43例43眼滴用布林佐胺滴眼液早晚各1次,共观察12 wk。观察的指标主要包括眼压、眼部症状以及不良反应等。<br> 结果：治疗组眼压从(24.20±3.01) mmHg 降至(16.77±2.89)mmHg；对照组从(23.87±3.47)mmHg降至(18.81±3.07)mmHg,两组用药前后眼压相比均有显著差异(P<0.01),各时间点两组间眼压相比存在统计学差异( P<0.05)。用药后治疗组结膜充血及眼痒明显重于对照组,但不妨碍继续用药。未发现其他眼部改变和全身副作用。<br> 结论：曲伏前列素对控制已行白内障超声乳化人工晶状体植入术的原发性开角型青光眼的眼压是高效和安全的。
目的：觀察麯伏前列素滴眼液對已行白內障超聲乳化人工晶狀體植入術的原髮性開角型青光眼患者的降眼壓效果及安全性。<br> 方法：採用隨機、單盲、平行對照試驗,選取白內障超聲乳化人工晶狀體植入術後的原髮性開角型青光眼患者,治療組入選43例43眼滴用麯伏前列素每日1次,對照組入選43例43眼滴用佈林佐胺滴眼液早晚各1次,共觀察12 wk。觀察的指標主要包括眼壓、眼部癥狀以及不良反應等。<br> 結果：治療組眼壓從(24.20±3.01) mmHg 降至(16.77±2.89)mmHg；對照組從(23.87±3.47)mmHg降至(18.81±3.07)mmHg,兩組用藥前後眼壓相比均有顯著差異(P<0.01),各時間點兩組間眼壓相比存在統計學差異( P<0.05)。用藥後治療組結膜充血及眼癢明顯重于對照組,但不妨礙繼續用藥。未髮現其他眼部改變和全身副作用。<br> 結論：麯伏前列素對控製已行白內障超聲乳化人工晶狀體植入術的原髮性開角型青光眼的眼壓是高效和安全的。
목적：관찰곡복전렬소적안액대이행백내장초성유화인공정상체식입술적원발성개각형청광안환자적강안압효과급안전성。<br> 방법：채용수궤、단맹、평행대조시험,선취백내장초성유화인공정상체식입술후적원발성개각형청광안환자,치료조입선43례43안적용곡복전렬소매일1차,대조조입선43례43안적용포림좌알적안액조만각1차,공관찰12 wk。관찰적지표주요포괄안압、안부증상이급불량반응등。<br> 결과：치료조안압종(24.20±3.01) mmHg 강지(16.77±2.89)mmHg；대조조종(23.87±3.47)mmHg강지(18.81±3.07)mmHg,량조용약전후안압상비균유현저차이(P<0.01),각시간점량조간안압상비존재통계학차이( P<0.05)。용약후치료조결막충혈급안양명현중우대조조,단불방애계속용약。미발현기타안부개변화전신부작용。<br> 결론：곡복전렬소대공제이행백내장초성유화인공정상체식입술적원발성개각형청광안적안압시고효화안전적。
AIM: To investigate the effect of lowering intraocular pressure ( IOP ) and side effect of travoprost ( TA ) on phacoemulsification and intraoclular lens ( IOL ) implantation in primary open-angle glaucoma ( POAG) . <br> METHODS: Patients with POAG already received surgery of phacoemulsification and IOL implantation were selected by randomized, single - blind, parallel group trial. TA was applied once a day in 43 patients (43 eyes) of treatment group and brinzolamide was used twice in 43 patients ( 43 eyes ) of control group. All patients were observed for 12wk. IOP, ocular symptom and adverse reaction etc. were observed. <br> RESULTS: The daily average IOP ( mean ± standard deviation) in the treatment group decreased from (24. 20±3.01)mmHg (1mmHg=0.133kPa) to (16.77±2.89)mmHg and that in the control group was from ( 23. 87±3. 47 ) mmHg to ( 18. 81± 3. 07 ) mmHg. IOP pre- and pro-treatment within two groups had significant difference ( P<0. 01), IOP between the groups at each time point had statistical difference (P<0. 05). Conjunetival congestion increased and itching in treatment group was obviously more serious than that in the control group, but the treatment could continue. No other ocular and systemic adverse events related to the drugs were found. <br> CONCLUSION: It is demonstrated that travoprost is highly effective and safe in reducing IOP in POAG already received surgery of phacoemulsification and IOL implantation.
